How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8375"
  ["article_id"]=>
  string(4) "8375"
  [1]=>
  string(56) "People fearful of taking part in vital clinical research"
  ["article_title"]=>
  string(56) "People fearful of taking part in vital clinical research"
  [2]=>
  string(150) "A review has found that fear about testing new treatments and possible side effects was the most common reason given by patients for not wanting to pa"
  ["short_description"]=>
  string(150) "A review has found that fear about testing new treatments and possible side effects was the most common reason given by patients for not wanting to pa"
  [3]=>
  string(161) "A review has found that fear about testing new treatments and possible side effects was the most common reason given by patients for not wanting to participate. "
  ["description"]=>
  string(161) "A review has found that fear about testing new treatments and possible side effects was the most common reason given by patients for not wanting to participate. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316104010.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316104010.htm"
  [15]=>
  string(19) "2020-03-16 22:40:10"
  ["add_date"]=>
  string(19) "2020-03-16 22:40:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:17"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

People fearful of taking part in vital clinical research

A review has found that fear about testing new treatments and possible side effects was the most common reason given by 

array(40) {
  [0]=>
  string(4) "8454"
  ["article_id"]=>
  string(4) "8454"
  [1]=>
  string(41) "QPS launches access-restricted laboratory"
  ["article_title"]=>
  string(41) "QPS launches access-restricted laboratory"
  [2]=>
  string(135) "The access-restricted bioanalysis lab will support research to develop treatments and vaccines for novel coronavirus and other viruses."
  ["short_description"]=>
  string(135) "The access-restricted bioanalysis lab will support research to develop treatments and vaccines for novel coronavirus and other viruses."
  [3]=>
  string(135) "The access-restricted bioanalysis lab will support research to develop treatments and vaccines for novel coronavirus and other viruses."
  ["description"]=>
  string(135) "The access-restricted bioanalysis lab will support research to develop treatments and vaccines for novel coronavirus and other viruses."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(149) "https://www.outsourcing-pharma.com/Article/2020/03/16/New-QPS-lab-offers-coronavirus-capabilities?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(149) "https://www.outsourcing-pharma.com/Article/2020/03/16/New-QPS-lab-offers-coronavirus-capabilities?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-16 22:30:00"
  ["add_date"]=>
  string(19) "2020-03-16 22:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:40"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:40"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

QPS launches access-restricted laboratory

The access-restricted bioanalysis lab will support research to develop treatments and vaccines for novel coronavirus and

array(40) {
  [0]=>
  string(4) "8376"
  ["article_id"]=>
  string(4) "8376"
  [1]=>
  string(86) "Nanostructured rubber-like material with optimal properties could replace human tissue"
  ["article_title"]=>
  string(86) "Nanostructured rubber-like material with optimal properties could replace human tissue"
  [2]=>
  string(150) "Researchers have created a new, rubber-like material with a unique set of properties, which could act as a replacement for human tissue in medical pro"
  ["short_description"]=>
  string(150) "Researchers have created a new, rubber-like material with a unique set of properties, which could act as a replacement for human tissue in medical pro"
  [3]=>
  string(243) "Researchers have created a new, rubber-like material with a unique set of properties, which could act as a replacement for human tissue in medical procedures. The material has the potential to make a big difference to many people's lives. "
  ["description"]=>
  string(243) "Researchers have created a new, rubber-like material with a unique set of properties, which could act as a replacement for human tissue in medical procedures. The material has the potential to make a big difference to many people's lives. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316090334.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/03/200316090334.htm"
  [15]=>
  string(19) "2020-03-16 21:03:34"
  ["add_date"]=>
  string(19) "2020-03-16 21:03:34"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:17"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Nanostructured rubber-like material with optimal properties could replace human tissue

Researchers have created a new, rubber-like material with a unique set of properties, which could act as a replacement f

array(40) {
  [0]=>
  string(4) "8352"
  ["article_id"]=>
  string(4) "8352"
  [1]=>
  string(119) "Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease"
  ["article_title"]=>
  string(119) "Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Suspected of Autoimmune Disease"
  [2]=>
  string(150) "SAN DIEGO, CA, March  16, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patien"
  ["short_description"]=>
  string(150) "SAN DIEGO, CA, March  16, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patien"
  [3]=>
  string(781) "
SAN DIEGO, CA, March  16, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has entered into a strategic partnership with Sonora Quest, the nation’s largest integrated laboratory system. The agreement provides preferred access through Sonora Quest in Arizona to Exagen’s AVISE testing. The testing can facilitate improved care through the differential diagnosis, prognosis, monitoring and therapeutic optimization of complex and incurable autoimmune rheumatic diseases. The details of the agreement are confidential.
"
  ["description"]=>
  string(781) "
SAN DIEGO, CA, March  16, 2020  (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has entered into a strategic partnership with Sonora Quest, the nation’s largest integrated laboratory system. The agreement provides preferred access through Sonora Quest in Arizona to Exagen’s AVISE testing. The testing can facilitate improved care through the differential diagnosis, prognosis, monitoring and therapeutic optimization of complex and incurable autoimmune rheumatic diseases. The details of the agreement are confidential.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(189) "http://www.globenewswire.com/news-release/2020/03/16/2001039/0/en/Exagen-Inc-Partners-with-Sonora-Quest-Laboratories-to-Offer-AVISE-Testing-for-Patients-Suspected-of-Autoimmune-Disease.html"
  ["blog_url"]=>
  string(189) "http://www.globenewswire.com/news-release/2020/03/16/2001039/0/en/Exagen-Inc-Partners-with-Sonora-Quest-Laboratories-to-Offer-AVISE-Testing-for-Patients-Suspected-of-Autoimmune-Disease.html"
  [15]=>
  string(19) "2020-03-16 20:19:00"
  ["add_date"]=>
  string(19) "2020-03-16 20:19:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:08"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Exagen Inc. Partners with Sonora Quest Laboratories to Offer AVISE Testing for Patients Su

SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transform

array(40) {
  [0]=>
  string(4) "8319"
  ["article_id"]=>
  string(4) "8319"
  [1]=>
  string(49) "2009 to 2015 Saw Increase in Hyperglycemic Events"
  ["article_title"]=>
  string(49) "2009 to 2015 Saw Increase in Hyperglycemic Events"
  [2]=>
  string(150) "MONDAY, March 16, 2020 -- From 2009 to 2015, there were increases in diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) events amo"
  ["short_description"]=>
  string(150) "MONDAY, March 16, 2020 -- From 2009 to 2015, there were increases in diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) events amo"
  [3]=>
  string(250) "MONDAY, March 16, 2020 -- From 2009 to 2015, there were increases in diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) events among adults, according to a study published online March 11 in Diabetes Care.&#nlStephen R. Benoit,..."
  ["description"]=>
  string(250) "MONDAY, March 16, 2020 -- From 2009 to 2015, there were increases in diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS) events among adults, according to a study published online March 11 in Diabetes Care.&#nlStephen R. Benoit,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(174) "https://www.drugs.com/news/2009-2015-saw-increase-hyperglycemic-events-88972.html?utm_source=ddc&utm_medium=rss&utm_campaign=2009+to+2015+Saw+Increase+in+Hyperglycemic+Events"
  ["blog_url"]=>
  string(174) "https://www.drugs.com/news/2009-2015-saw-increase-hyperglycemic-events-88972.html?utm_source=ddc&utm_medium=rss&utm_campaign=2009+to+2015+Saw+Increase+in+Hyperglycemic+Events"
  [15]=>
  string(19) "2020-03-16 20:00:52"
  ["add_date"]=>
  string(19) "2020-03-16 20:00:52"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:43"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

2009 to 2015 Saw Increase in Hyperglycemic Events

MONDAY, March 16, 2020 -- From 2009 to 2015, there were increases in diabetic ketoacidosis (DKA) and hyperglycemic hyper

array(40) {
  [0]=>
  string(4) "8320"
  ["article_id"]=>
  string(4) "8320"
  [1]=>
  string(71) "Poll: Many Parents Not Talking to Children About Inappropriate Touching"
  ["article_title"]=>
  string(71) "Poll: Many Parents Not Talking to Children About Inappropriate Touching"
  [2]=>
  string(150) "MONDAY, March 16, 2020 -- Many parents are not having talks with their preschool or school-age children about inappropriate touching, according to a n"
  ["short_description"]=>
  string(150) "MONDAY, March 16, 2020 -- Many parents are not having talks with their preschool or school-age children about inappropriate touching, according to a n"
  [3]=>
  string(256) "MONDAY, March 16, 2020 -- Many parents are not having talks with their preschool or school-age children about inappropriate touching, according to a new C.S. Mott Children's Hospital national poll from the University of Michigan in Ann Arbor.&#nlThe..."
  ["description"]=>
  string(256) "MONDAY, March 16, 2020 -- Many parents are not having talks with their preschool or school-age children about inappropriate touching, according to a new C.S. Mott Children's Hospital national poll from the University of Michigan in Ann Arbor.&#nlThe..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(216) "https://www.drugs.com/news/poll-many-parents-not-talking-children-inappropriate-touching-88964.html?utm_source=ddc&utm_medium=rss&utm_campaign=Poll%3A+Many+Parents+Not+Talking+to+Children+About+Inappropriate+Touching"
  ["blog_url"]=>
  string(216) "https://www.drugs.com/news/poll-many-parents-not-talking-children-inappropriate-touching-88964.html?utm_source=ddc&utm_medium=rss&utm_campaign=Poll%3A+Many+Parents+Not+Talking+to+Children+About+Inappropriate+Touching"
  [15]=>
  string(19) "2020-03-16 20:00:28"
  ["add_date"]=>
  string(19) "2020-03-16 20:00:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:43"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Poll: Many Parents Not Talking to Children About Inappropriate Touching

MONDAY, March 16, 2020 -- Many parents are not having talks with their preschool or school-age children about inappropri

array(40) {
  [0]=>
  string(4) "8321"
  ["article_id"]=>
  string(4) "8321"
  [1]=>
  string(61) "Many Motor Vehicle Crash Fatalities Involve Low Blood Alcohol"
  ["article_title"]=>
  string(61) "Many Motor Vehicle Crash Fatalities Involve Low Blood Alcohol"
  [2]=>
  string(150) "MONDAY, March 16, 2020 -- A considerable number of motor vehicle crash fatalities involve a low blood alcohol concentration, according to a study publ"
  ["short_description"]=>
  string(150) "MONDAY, March 16, 2020 -- A considerable number of motor vehicle crash fatalities involve a low blood alcohol concentration, according to a study publ"
  [3]=>
  string(254) "MONDAY, March 16, 2020 -- A considerable number of motor vehicle crash fatalities involve a low blood alcohol concentration, according to a study published online March 16 in the American Journal of Preventive Medicine.&#nlMarlene C. Lira, from Boston..."
  ["description"]=>
  string(254) "MONDAY, March 16, 2020 -- A considerable number of motor vehicle crash fatalities involve a low blood alcohol concentration, according to a study published online March 16 in the American Journal of Preventive Medicine.&#nlMarlene C. Lira, from Boston..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(204) "https://www.drugs.com/news/many-motor-vehicle-crash-fatalities-involve-low-blood-alcohol-88971.html?utm_source=ddc&utm_medium=rss&utm_campaign=Many+Motor+Vehicle+Crash+Fatalities+Involve+Low+Blood+Alcohol"
  ["blog_url"]=>
  string(204) "https://www.drugs.com/news/many-motor-vehicle-crash-fatalities-involve-low-blood-alcohol-88971.html?utm_source=ddc&utm_medium=rss&utm_campaign=Many+Motor+Vehicle+Crash+Fatalities+Involve+Low+Blood+Alcohol"
  [15]=>
  string(19) "2020-03-16 20:00:15"
  ["add_date"]=>
  string(19) "2020-03-16 20:00:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:43"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:43"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Many Motor Vehicle Crash Fatalities Involve Low Blood Alcohol

MONDAY, March 16, 2020 -- A considerable number of motor vehicle crash fatalities involve a low blood alcohol concentrat

array(40) {
  [0]=>
  string(4) "8353"
  ["article_id"]=>
  string(4) "8353"
  [1]=>
  string(88) "Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update"
  ["article_title"]=>
  string(88) "Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update"
  [2]=>
  string(155) "Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of eso"
  ["short_description"]=>
  string(155) "Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of eso"
  [3]=>
  string(416) "Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis 
Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis
"
  ["description"]=>
  string(416) "Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis 
Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH-RX trial for the prevention of esophageal varices in patients with NASH cirrhosis
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(159) "http://www.globenewswire.com/news-release/2020/03/16/2000999/0/en/Galectin-Therapeutics-Reports-Fiscal-2019-Financial-Results-and-Provides-Business-Update.html"
  ["blog_url"]=>
  string(159) "http://www.globenewswire.com/news-release/2020/03/16/2000999/0/en/Galectin-Therapeutics-Reports-Fiscal-2019-Financial-Results-and-Provides-Business-Update.html"
  [15]=>
  string(19) "2020-03-16 20:00:00"
  ["add_date"]=>
  string(19) "2020-03-16 20:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:08"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:08"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update

Addition of Pol F. Boudes, M.D. as Chief Medical Officer strengthens executive team for launch of Galectin’s NASH

array(40) {
  [0]=>
  string(4) "8406"
  ["article_id"]=>
  string(4) "8406"
  [1]=>
  string(54) "SCFA supplement could improve efficacy of MS treatment"
  ["article_title"]=>
  string(54) "SCFA supplement could improve efficacy of MS treatment"
  [2]=>
  string(150) "Supplementation with the short-chain fatty acid propionic acid (PA) could help reduce excessive inflammatory processes in autoimmune diseases like mul"
  ["short_description"]=>
  string(150) "Supplementation with the short-chain fatty acid propionic acid (PA) could help reduce excessive inflammatory processes in autoimmune diseases like mul"
  [3]=>
  string(202) "Supplementation with the short-chain fatty acid propionic acid (PA) could help reduce excessive inflammatory processes in autoimmune diseases like multiple sclerosis (MS) and improve treatment outcomes."
  ["description"]=>
  string(202) "Supplementation with the short-chain fatty acid propionic acid (PA) could help reduce excessive inflammatory processes in autoimmune diseases like multiple sclerosis (MS) and improve treatment outcomes."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(158) "https://www.nutraingredients.com/Article/2020/03/16/SCFA-supplement-could-improve-efficacy-of-MS-treatment?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(158) "https://www.nutraingredients.com/Article/2020/03/16/SCFA-supplement-could-improve-efficacy-of-MS-treatment?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-16 20:00:00"
  ["add_date"]=>
  string(19) "2020-03-16 20:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:26"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:26"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

SCFA supplement could improve efficacy of MS treatment

Supplementation with the short-chain fatty acid propionic acid (PA) could help reduce excessive inflammatory processes i

array(40) {
  [0]=>
  string(4) "8282"
  ["article_id"]=>
  string(4) "8282"
  [1]=>
  string(53) "Pancreas app now available for type I diabetics in UK"
  ["article_title"]=>
  string(53) "Pancreas app now available for type I diabetics in UK"
  [2]=>
  string(150) "The launch is a “major stepping stone” towards providing “widely available, clinically proven, and user friendly artificial pancreas"
  ["short_description"]=>
  string(150) "The launch is a “major stepping stone” towards providing “widely available, clinically proven, and user friendly artificial pancreas"
  [3]=>
  string(198) "The launch is a “major stepping stone” towards providing “widely available, clinically proven, and user friendly artificial pancreas technology to people with type I diabetes.""
  ["description"]=>
  string(198) "The launch is a “major stepping stone” towards providing “widely available, clinically proven, and user friendly artificial pancreas technology to people with type I diabetes.""
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(93) "http://www.pharmatimes.com/news/pancreas_app_now_available_for_type_i_diabetics_in_uk_1329301"
  ["blog_url"]=>
  string(93) "http://www.pharmatimes.com/news/pancreas_app_now_available_for_type_i_diabetics_in_uk_1329301"
  [15]=>
  string(19) "2020-03-16 19:56:10"
  ["add_date"]=>
  string(19) "2020-03-16 19:56:10"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:41"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Pancreas app now available for type I diabetics in UK

The launch is a “major stepping stone” towards providing “widely available, clinically proven, and use

array(40) {
  [0]=>
  string(4) "8283"
  ["article_id"]=>
  string(4) "8283"
  [1]=>
  string(59) "Merck, Pfizer terminate Bavencio head and neck cancer trial"
  ["article_title"]=>
  string(59) "Merck, Pfizer terminate Bavencio head and neck cancer trial"
  [2]=>
  string(87) "The decision follows advice from the trial's independent data monitoring committee."
  ["short_description"]=>
  string(87) "The decision follows advice from the trial's independent data monitoring committee."
  [3]=>
  string(87) "The decision follows advice from the trial's independent data monitoring committee."
  ["description"]=>
  string(87) "The decision follows advice from the trial's independent data monitoring committee."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(99) "http://www.pharmatimes.com/news/merck,_pfizer_terminate_bavencio_head_and_neck_cancer_trial_1329296"
  ["blog_url"]=>
  string(99) "http://www.pharmatimes.com/news/merck,_pfizer_terminate_bavencio_head_and_neck_cancer_trial_1329296"
  [15]=>
  string(19) "2020-03-16 19:51:03"
  ["add_date"]=>
  string(19) "2020-03-16 19:51:03"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:41"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Merck, Pfizer terminate Bavencio head and neck cancer trial

The decision follows advice from the trial's independent data monitoring committee.

array(40) {
  [0]=>
  string(4) "8284"
  ["article_id"]=>
  string(4) "8284"
  [1]=>
  string(42) "COVID-19: Eli Lilly, Elsevier hop on board"
  ["article_title"]=>
  string(42) "COVID-19: Eli Lilly, Elsevier hop on board"
  [2]=>
  string(150) "Eli Lilly and AbCellera have plans to co-develop antibody products, and Elsevier is set to make all of its research and data content available on PubM"
  ["short_description"]=>
  string(150) "Eli Lilly and AbCellera have plans to co-develop antibody products, and Elsevier is set to make all of its research and data content available on PubM"
  [3]=>
  string(153) "Eli Lilly and AbCellera have plans to co-develop antibody products, and Elsevier is set to make all of its research and data content available on PubMed."
  ["description"]=>
  string(153) "Eli Lilly and AbCellera have plans to co-develop antibody products, and Elsevier is set to make all of its research and data content available on PubMed."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "4"
  ["rss_id"]=>
  string(1) "4"
  [14]=>
  string(81) "http://www.pharmatimes.com/news/covid-19_eli_lilly,_elsevier_hop_on_board_1329294"
  ["blog_url"]=>
  string(81) "http://www.pharmatimes.com/news/covid-19_eli_lilly,_elsevier_hop_on_board_1329294"
  [15]=>
  string(19) "2020-03-16 19:49:11"
  ["add_date"]=>
  string(19) "2020-03-16 19:49:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:28:41"
  ["create_at"]=>
  string(19) "2020-03-19 11:28:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

COVID-19: Eli Lilly, Elsevier hop on board

Eli Lilly and AbCellera have plans to co-develop antibody products, and Elsevier is set to make all of its research and